| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.0000124890.40436.77 |
| P698 | PubMed publication ID | 15001452 |
| P2093 | author name string | Hugh S Markus | |
| Juan Carlos Kaski | |||
| Zoltan Kaposzta | |||
| Jagdip S Sidhu | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-rosiglitazone | Q424771 |
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 930-934 | |
| P577 | publication date | 2004-03-04 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus | |
| P478 | volume | 24 |
| Q46961262 | 67 th annual meeting of the American Diabetes Association |
| Q37098328 | A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol |
| Q36012843 | Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis |
| Q33639520 | Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction |
| Q37965656 | Advances in noninvasive imaging for evaluating clinical risk and guiding therapy in carotid atherosclerosis. |
| Q46891969 | Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience |
| Q43109248 | Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis |
| Q36398075 | Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions |
| Q37563962 | Antidiabetic agents and cardiovascular risk in type 2 diabetes |
| Q42349595 | Approaches to treatment of type 2 diabetes |
| Q36857541 | Atherosclerosis in diabetes and insulin resistance |
| Q37786650 | Atherosclerosis regression and high-density lipoproteins |
| Q46591730 | Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study |
| Q37153031 | Cardiovascular disease and modifiable cardiometabolic risk factors |
| Q46028082 | Cardiovascular disease and modifiable cardiometabolic risk factors. |
| Q36679594 | Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents |
| Q34722085 | Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo |
| Q61805906 | Comparative effects of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on carotid artery intima-media thickness progression: a network meta-analysis |
| Q37702666 | Contribution of subcutaneous abdominal fat on ultrasonography to carotid atherosclerosis in patients with type 2 diabetes mellitus |
| Q36321268 | Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial |
| Q44424665 | Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial |
| Q36405834 | Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study |
| Q37430999 | Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production |
| Q37738154 | Does choice of antidiabetes therapy influence macrovascular outcomes? |
| Q36712986 | Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors |
| Q36805400 | Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes |
| Q64982670 | Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. |
| Q37167569 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study |
| Q36503391 | Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients |
| Q37259541 | Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation |
| Q51472462 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. |
| Q35011826 | Establishment and ultrasound characteristics of atherosclerosis in rhesus monkey |
| Q46447890 | Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease |
| Q36684465 | Flow-mediated signaling modulates endothelial cell phenotype. |
| Q40109736 | Haplotype analysis of PPARγ C681G and intron CT variants. Positive association with essential hypertension |
| Q36783681 | Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs |
| Q36232378 | Impact of thiazolidinedione therapy on atherogenesis |
| Q33810041 | Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension |
| Q36390892 | Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus |
| Q46503090 | Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient |
| Q61853244 | Insulin Resistance, Inflammation, and Vascular Disease in Nondiabetic Predialysis Chronic Kidney Disease Patients |
| Q36319330 | Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action |
| Q37606015 | Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? |
| Q35666715 | Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity |
| Q36444362 | Muraglitazar and the FDA: what constitutes drug safety? |
| Q46287210 | PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes |
| Q57892049 | PPAR attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells |
| Q37788729 | PPAR-γ Agonism for Cardiovascular and Renal Protection |
| Q37992593 | Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes |
| Q24186319 | Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack |
| Q24201174 | Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack |
| Q90611354 | Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack |
| Q47380989 | Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. |
| Q37943863 | Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease |
| Q37861955 | Peroxisome proliferator-activated receptors and atherosclerosis. |
| Q35890826 | Peroxisome proliferator-activated receptors and cardiovascular remodeling |
| Q36510464 | Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications |
| Q35636191 | Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease |
| Q37357337 | Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus |
| Q37310692 | Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways |
| Q36844378 | Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies |
| Q36569766 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects |
| Q36407383 | Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality |
| Q37385198 | Potential of glucose-lowering drugs to reduce cardiovascular events |
| Q28183142 | Prevention of coronary heart disease in diabetes |
| Q36383197 | Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets |
| Q36262404 | Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases |
| Q33575808 | Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study |
| Q37264420 | Reassessing the cardiovascular risks and benefits of thiazolidinediones |
| Q51477941 | Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. |
| Q37275571 | Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial |
| Q35040072 | Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits |
| Q46558857 | Rosiglitazone improves aortic arginine transport, through inhibition of PKCalpha, in uremic rats |
| Q46582056 | Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. |
| Q59193422 | Setting the record straight on TIDE: a lost opportunity for patients with diabetes |
| Q36124203 | Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial |
| Q81004047 | TZDs and diabetes: testing the waters |
| Q35794254 | The Role of PPARgamma in pulmonary vascular disease |
| Q54152623 | The cardiovascular safety of rosiglitazone |
| Q42831071 | The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk |
| Q42868308 | The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: A meta-analysis |
| Q37079828 | The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. |
| Q36511476 | The role of PPARs in the microvascular dysfunction in diabetes. |
| Q35925357 | The role of peroxisome proliferator-activated receptors in pulmonary vascular disease |
| Q36405110 | The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis |
| Q36480698 | Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art. |
| Q37142138 | Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update |
| Q33827960 | Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes |
| Q36052956 | Thiazolidinediones and cardiovascular disease |
| Q36632030 | Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism |
| Q36996294 | Thiazolidinediones as anti-inflammatory and anti-atherogenic agents |
| Q36426782 | Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases |
Search more.